natgillin/translations-raw huggingface dataset:
Da alvorlig og livstruende hepatotoksicitet i kontrollerede og ukontrollerede studier fortrinsvis er set hos patienter med en hiv-1-virusbelastning i plasma på 50 kopier/ml eller højere, skal nevirapin ikke initieres hos kvinder med CD4-celletal større end 250 celler/mm eller hos mænd med CD4-celletal større end 
As serious and life threatening hepatotoxicity has been observed in controlled and uncontrolled studies predominantly in patients with a plasma HIV-1 viral load of 50 copies/ml or higher, nevirapine should not be initiated in adult females with CD4 cell counts greater than 250 cells/mm
EU/1/97/055/009 [90 depottabletter] 
EU/1/97/055/009 [90 prolonged-release]
Samtidig behandling med naturlægemidler indeholdende perikon (Hypericum perforatum) pga. risiko for nedsat plasmakoncentration og reduceret klinisk effekt af nevirapin (Se pkt. 
Coadministration with herbal preparations containing St. John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).
Emtricitabin hæmmer ikke humane CYP-enzymer. 
Emtricitabine is not an inhibitor of human CYP 450 enzymes.
Rifabutin 150 eller 300 mg 4 gange daglig 
Rifabutin 150 or 300 mg QD
Fordi nevirapin fremkalder sin egen metabolisme ved multipel dosering, viser dette enkeltdosis studie ikke nødvendigvis den påvirkning af leveren, som ses ved multipel dosering (se pkt. 
Because nevirapine induces its own metabolism with multiple dosing, this single dose study may not reflect the impact of hepatic impairment on multiple dose pharmacokinetics (see section
Til brug herfor anvendes den medfølgende dispenseringssprøjte. 
This is assisted by the use of the supplied dispensing syringe.
Den anbefalede dosis Viramune er 20 ml (200 mg) oral suspension 1 gang daglig i de første 14 dage (denne optrapningsperiode bør benyttes, idet den har vist sig at mindske hyppigheden af udslæt) efterfulgt af 20 ml (200 mg) oral suspension 2 gange dagligt i kombination med mindst to antiretrovirale lægemidler. 
The recommended dose for Viramune is 20 ml (200 mg) oral suspension once daily for the first 14 days (this lead-in period should be used because it has been found to lessen the frequency of rash), followed by 20 ml (200 mg) oral suspension twice daily, in combination with at least two additional antiretroviral agents.
Genotypisk analyse af isolater fra antiretroviralnaive patienter, der havde oplevet virologisk svigt (n=71) med nevirapin administreret én gang dagligt (n=25) eller to gange dagligt (n=46) i kombination med lamivudin og stavudin i 48 uger, viste, at isolater fra 8/25 henholdsvis 23/46 patienter indeholdt en eller flere af de følgende NNRTI-resistens-associerede substitutioner: Y181C, K101E, G190A, K103N, V106A/M, V108I, Y188C/L, A98G, F227L og M230L. 
Genotypic analysis of isolates from antiretroviral naïve patients experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine for 48 weeks showed that isolates from 8/25 and 23/46 patients, respectively, contained one or more of the following NNRTI resistance-associated substitutions: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L and M230L.
Det multinationale 2NN-studie med Viramune 200 mg indeholdt et farmakokinetisk substudie med 1077 patienter, hvoraf de 391 var kvinder. 
In the multinational 2NN study with Viramune immediate-release, a population pharmacokinetic substudy of 1077 patients was performed that included 391 females.
Patienter, der skifter fra Viramune tabletter til Viramune depottabletter I fase III-studiet TRANxITION (studie 1100.1526) blev sikkerhed og antiviral aktivitet hos patienter, der skifter fra Viramune 200 mg til Viramune i depotform evalueret. 
Patients switching from Viramune immediate-release to Viramune prolonged-release TRANxITION (study 1100.1526) is a Phase 3 study to evaluate safety and antiviral activity in patients switching from Viramune immediate-release to Viramune prolonged-release.
Viramune indeholder saccharose, sorbitol, methylparahydroxybenzoat, propylparahydroxybenzoat og natrium 
Viramune contains sucrose, sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate and sodium
- tidligere ubehandlede patienter, der har forhøjede CD4-celletal ved starten af behandling med Viramune (kvinder med over 250 celler/mm 3, mænd med over 400 celler/mm - tidligere behandlede patienter med påviselig hiv-1 plasma viral niveau og højere CD4-celletal ved behandlingsstart med Viramune (kvinder mere end 250 celler/mm 3, mænd mere end 400 
- treatment-naïve patients with higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³) - pre-treated patients with detectable HIV-1 plasma viral load and higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³)
3 12 gange større risiko for symptomatisk leverpåvirkning sammenlignet med kvinder med CD4-celletal <250 celler/mm 
3 had a 12 fold higher risk of symptomatic hepatic adverse reactions compared to women with CD4 counts <250 cells/mm
Farvede patienter (n = 80/gruppe) i studie 1100.1486 havde ca. 30 % højere trough-koncentrationer end kaukasiske patienter (250-325 patienter/gruppe) med Viramune 200 mg såvel som med Viramune depottabletter over 48 ugers behandling med 400 mg/dag. 
Black patients (n=80/group) in study 1100.1486 showed approximately 30% higher trough concentrations than Caucasian patients (250-325 patients/group) in both the Viramune immediate-release and Viramune prolonged-release treatment groups over 48 weeks of treatment at 400 mg/day.
In vitro er der set hurtig udvikling af hiv-stammer, som er krydsresistente over for NNRT-hæmmere. 
Rapid emergence of HIV-strains which are cross-resistant to NNRTIs has been observed in vitro.
3 for mænd) ved initiering af nevirapin-behandling, og som har et detekterbar plasmaniveau af hiv-1-RNA - dvs. ≥50 kopier/ml - har en højere risiko for leverpåvirkninger. 
3 in adult males) at the initiation of nevirapine therapy are associated with a greater risk of hepatic adverse reactions if the patient has detectable plasma HIV-1 RNA - i.e. a concentration ≥ 50 copies/ml - at the initiation of nevirapine.
Informer din læge, hvis du oplever nogen af de følgende kliniske symptomer på leverskade - appetitløshed - kvalme - opkastning - huden bliver gul (gulsot) - mavesmerter. 
Tell your doctor if you experience any of the following clinical symptoms of liver damage: - loss of appetite - feeling sick (nausea) - vomiting - yellow skin (jaundice) - abdominal pain.
Behandling med nevirapin må ikke genstartes efter svær lever-, hud- eller overfølsomhedsreaktioner (se pkt. 
Nevirapinemust not be restarted following severe hepatic, skin or hypersensitivity reactions (see section 4.3).
Det anbefales ikke at coadministrere fosamprenavir og Viramune, hvis fosamprenavir ikke co-administreres sammen med ritonavir (se pkt. 
It is not recommended to coadminister fosamprenavir and Viramune if fosamprenavir is not coadministered with ritonavir (see section 4.4).
I et masse-balance/ekskretionsstudie med 8 raske, frivillige, mandlige forsøgspersoner, som blev behandlet indtil steady state med nevirapin 200 mg 2 gange dagligt efterfulgt af en enkelt dosis på 50 mg af 14C-nevirapin blev tilnærmelsesvis 91,4±10,5 % af den radioaktivt mærkede dosis genfundet: I urinen (81,3±11,1 %) hvilket repræsenterer den primære ekskretionsvej sammenlignet med fæces (10,1±1,5 %). 
In a mass balance/excretion study in eight healthy male volunteers dosed to steady state with nevirapine 200 mg given twice daily followed by a single 50 mg dose of 14C-nevirapine, approximately 91.4  10.5 % of the radiolabelled dose was recovered, with urine (81.3  11.1 %) representing the primary route of excretion compared to faeces (10.1  1.5 %).
Der var ingen forskelle i forhold til doseringform (200 mg tabletter to gange dagligt eller depotform én gang dagligt). 
There were no differences based on the formulation taken (immediate-release twice daily or prolonged-release once daily).
Enkeltdosis-farmakokinetikken af nevirapin er blevet sammenlignet mellem 23 patienter med enten let (50≤CLcr< 80 ml/min), moderat (30 ≤ CLcr < 50 ml/min) eller svært nedsat nyrefunktion (CLcr < 30 ml/min) eller dialysekrævende end-stage nyresygdom (ESRD) og 8 patienter med normal nyrefunktion (CLcr > 80 ml/min). 
Renal impairment: The single-dose pharmacokinetics of nevirapine has been compared in 23 patients with either mild (50  CLcr  80 ml/min), moderate (30  CLcr  50 ml/min) or severe renal dysfunction (CLcr  30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr  80 ml/min).
De nedenfor anførte frekvenser er baseret på incidensrater for bivirkninger set hos de grupper, der fik Viramune med umiddelbar frigivelse (optrapningsfase, tabel 1) og Viramune depottabletter (randomiseret /vedligeholdelse, tabel 2) i det kliniske studie 1100.1486, hvor 1.068 patienter blev behandlet med Viramune og tenofovir/emtricitabin som tillægsbehandling. 
The frequencies given below are based on crude incidence rates of adverse reactions observed in the Viramune immediate-release (lead-in phase, table 1) and Viramune prolonged-release (randomised-phase/maintenance phase, table 2) groups of clinical study 1100.1486 with 1,068 patients exposed to Viramune on a backbone of tenofovir/emtricitabine.
Patienter i samtidig behandling med nevirapin og zidovudinog især pædiatriske patienter, patienter, som får højere doser af zidovudin, samt patienter med ringe knoglemarvsreserve, specielt patienter med fremskreden hiv-sygdom, har derfor øget risiko for granulocytopeni. 
Therefore, patients who receive nevirapine and zidovudine concomitantly and especially paediatric patients and patients who receive higher zidovudine doses or patients with poor bone marrow reserve, in particular those with advanced HIV disease, have an increased risk of granulocytopenia.
Endvidere kan risikoen for hepatotoksicitet hos mor og barn ikke udelukkes i de tilfælde, hvor Viramune gives som enkeltdosis for at forebygge vertikal transmission af hiv-1-infektion. 
Furthermore, in the case Viramune is used as single dose to prevent vertical transmission of HIV-1 infection, the risk of hepatotoxicity in mother and child cannot be excluded.
Især patienter med et hiv-1 viralt plasmaniveau på 50 kopier/ml eller flere og kvinder med CD4-celletal > 250 celler/mm 
Predominantly patients with a plasma HIV-1 viral load of 50 copies/ml or higher, women with CD4 counts >250 cells/mm
Det er meget vigtigt, at du kun tager én Viramune tablet om dagen i de første 14 dage ("optrapningsperioden"). 
It is very important that you take only one Viramune tablet a day for the first 14 days (“lead-in” period).
Viramune oral suspension, hvor doseringen kan tilpasses efter vægt eller legemsoverfladeareal, kan anvendes til børn under 16 år, der vejer mindre end 50 kg, eller hvis legemsoverfladeareal er mindre end 1,25 m² (se produktresuméet for Viramune oral suspension). 
An oral suspension dosage form, which can be dosed according to body weight or body surface area, is available for children in this age group weighing less than 50 kg or whose body surface area is below 1.25 m2 (please refer to the
Det anbefales ikke at coadministrere atazanavir/ritonavir og Viramune (se pkt. 
It is not recommended to coadminister atazanavir/ritonavir and Viramune (see section 4.4).
Nogle patienter, som blev behandlet med nevirapin, udviklede alvorlige og livstruende hudreaktioner, herunder Stevens-Johnsons syndrom (SJS) og toksisk epidermal nekrolyse (TEN). 
Severe and life-threatening skin reactions have occurred in patients treated with nevirapine, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
LÆGEMIDLETS NAVN Viramune 50 mg/5 ml, oral suspension 
NAME OF THE MEDICINAL PRODUCT Viramune 50 mg/5 ml oral suspension
Patienter skal informeres om, at træthed kan optræde som en bivirking ved Viramune-behandlingen. 
However, patients should be advised that they may experience adverse reactions such as fatigue during treatment with Viramune.
Sjælden (kan forekomme hos op til 1 ud af 1.000 patienter): - pludselig og alvorlig leverbetændelse (fulminant leverbetændelse) - lægemiddelforårsaget udslæt (med eosinofili og systemiske symptomer) 
Rare (may affect up to 1 in 1000 people): - sudden and intense inflammation of the liver (fulminant hepatitis) - drug reaction with systemic symptoms (drug reaction with eosinophilia and systemic symptoms)
Nevirapin bør ikke bruges til patienter med svært nedsat leverfunktion (Child-Pugh C, se pkt. 
Nevirapine should not be used in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Enkeltdosis farmakokinetik for nevirapin med umiddelbar frigivelse er blevet sammenlignet mellem 23 patienter med enten let (50 ≤ CLcr < 80 ml/min, moderat (30 ≤ CLcr < 50 ml/min) eller svært nedsat nyrefunktion (CLcr < 30 ml/min) eller dialysekrævende end-stage nyresygdom (ESRD), og 8 patienter med normal nyrefunktion (CLcr > 80 ml/min). 
Renal impairment: The single-dose pharmacokinetics of nevirapine immediate-release has been compared in 23 patients with either mild (50  CLcr  80 ml/min), moderate (30  CLcr  50 ml/min) or severe renal dysfunction (CLcr  30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr  80 ml/min).
Hvis du får alvorlige hududslæt eller overfølsomhedsreaktioner (allergiske reaktioner som kan forekomme i form af hududslæt), samtidig med andre bivirkninger såsom - feber - blæredannelse - sår i munden - øjenbetændelse - hævelse i ansigtet - generel hævelse - åndenød - muskel- eller ledsmerter - generel følelse af at være syg - eller mavesmerter 
If you experience severe rash or hypersensitivity (allergic reactions that may appear in the form of rash) accompanied by other side effects such as - fever, - blistering, - mouth sores, - inflammation of the eye, - swelling of the face, - general swelling, - shortness of breath, - muscle or joint pain, - general feelings of illness, - or abdominal pain
Hvis der opstår overfølsomhedsreaktioner, karakteriseret ved udslæt med konstitutionelle symptomer såsom feber, artralgi, myalgi og lymfadenopati samt organpåvirkning, såsom hepatitis, eosinofili, granulocytopeni og nyresvigt, skal nevirapin stoppes permanent og ikke genintroduceres (se pkt. 
If a hypersensitivity reaction occurs, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction, nevirapine must be permanently stopped and not be reintroduced (see section 4.3).
Viramune tabletter skal sluges. 
Only take Viramune tablets by mouth.
Patienter, som udvikler udslæt under de 14-dages lead-in periode, må ikke få initieret behandlingen med Viramune depottabletter, før udslættet er forsvundet. 
Patients experiencing rash during the 14-day lead-in period should not initiate treatment with Viramune prolonged-release tablets until the rash has resolved.
Tag ikke Viramune hvis du er blevet udsat for hiv, med mindre du er blevet diagnosticeret med hiv og lægen har foreskrevet det. Viramune kan ikke helbrede en hiv-infektion. 
Do not take Viramune after an exposure to HIV unless you have been diagnosed with HIV and instructed to do so by your doctor.
Legemsoverfladeareal (BSA) område (m 
BSA range (m
- Aktivt stof: Nevirapin - Øvrige indholdsstoffer: - mikrokrystallinsk cellulose, - lactose (som monohydrat), - povidon, - natriumstivelsesglycolat, - kolloid silica og - magnesiumstearat. 
- The other ingredients are: microcrystalline cellulose, lactose (as monohydrate), povidone K25, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate.
Lactose: Ved den maksimale, anbefalede daglige dosis af Viramune depottabletter indtages 400 mg lactose. 
Lactose: Viramune prolonged-release tablets contain 400 mg of lactose per maximum recommended daily dose.
Dosis for børn er 4 mg/kg legemsvægt eller 150 mg/m² legemsoverfladeareal 1 gang dagligt i de første 14 dage af behandlingen (optrapningsfasen). 
The dose for children is 4 mg/kg body weight or 150 mg/m2 body surface area once a day for the first
Zidovudin 100-200 mg 3 gange dagligt 
Zidovudine 100-200 mg TID
Nogle risikofaktorer for at udvikle alvorlige kutane reaktioner er blevet identificeret og inkluderer undladelse i at følge den anbefalede lead-in dosis i løbet af optrapningsperioden og en lang forsinkelse mellem de første symptomer og lægekonsultation. 
Some risk factors for developing serious cutaneous reactions have been identified; they include failure to follow the initial dosing during the lead-in period and a long delay between the initial symptoms and medical consultation.
I ACTG 245, et dobbeltblindt, placebokontrolleret studie, var forekomsten af alvorlig, lægemiddelrelateret granulocytopeni 5/305 (1,6 %). 
In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6 %).
55216 Ingelheim am Rhein Tyskland eller 
55216 Ingelheim am Rhein Germany or
Viramune forhandles også som 200 mg tabletter til patienter på 16 år og derover eller til ældre børn specielt unge, der vejer 50 kg eller mere, eller hvis legemsoverfladearealet er over 1,25 m². 
Viramune is also available as a 200 mg tablet for patients 16 years and older, or for older children, particularly adolescents, weighing 50 kg or more or whose BSA is above 1.25 m
LÆGEMIDLETS NAVN Viramune 50 mg/5 ml oral suspension nevirapin 
NAME OF THE MEDICINAL PRODUCT Viramune 50 mg/5 ml oral suspension nevirapine
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER 1 ml oral suspension indeholder 10 mg nevirapin (som hemihydrat) 
STATEMENT OF ACTIVE SUBSTANCE(S) Each ml of oral suspension contains 10 mg of nevirapine (as hemihydrate)
Behandlingsnaive kvindelige patienter og behandlingsnaive patienter med høje CD4-celletal ved initiering af behandling med nevirapin har en højere risiko for leverpåvirkninger. 
Female gender and higher CD4 counts at the initiation of nevirapine therapy in treatment-naïve patients is associated with increased risk of hepatic adverse reactions.
Viramune 200 mg tabletter, kan anvendes i den ovenfor beskrevne dosering til større børn, specielt unge, der er yngre end 16 år, og som vejer mere end 50 kg eller hvis legemsoverfladeareal er mere end 1,25 m² i henhold til Mosteller formlen. 
Viramune 200 mg tablets, following the dosing schedule described above, are suitable for larger children, particularly adolescents, below the age of 16 who weigh more than 50 kg or whose body surface area is above 1.25 m2 according to the Mosteller formula.
Som forklaret under ”Advarsler og forsigtighedsregler” så vil din læge følge dig ved at få undersøgt leverfunktionen eller undersøge dig for bivirkninger såsom hududslæt. 
As explained in 'Warnings and precautions', above, your doctor will monitor you with liver tests or for undesirable effects such as rash.
Stivhed, ømhed og smerter i leddene (især hofte, knæ og skulder) samt besvær med at bevæge sig er tegn på knoglenekrose. 
Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement.
Mindre børn kan tage depottabletter i lavere styrker eller en oral suspension (mikstur). 
For smaller children smaller prolonged-release tablets or an oral suspension liquid form are available.
De er ca. 9 mm i diameter, og præget med V01 og firmalogo. 
The prolonged-release tablets are approximately 9 mm in diameter, debossed with V01 on one side and company symbol on the other side.
Lægen vil informere dig om den korrekte dosis til barnet og vil løbende kontrollere barnets vægt og legemsoverfladeareal, for at sikre den korrekte dosering. 
Your child's doctor will continually check your child's weight or body surface area to ensure the correct dose.
I studie 1100.1090 blev bivirkningen granolucytopeni ( n=28) rapporteret hyppigere i placebogruppen (3,3%) end i nevirapingruppen (2,5%). 
In study 1100.1090, from which the majority of related adverse events (n=28) were received, patients on placebo had a higher incidence of events of granulocytopenia (3.3 %) than patients on nevirapine
I studie 1100.1526 (TRANxITION) blev patienterne efter minimum 18 ugers behandling medViramune 200 mg tabletter to gange dagligt, randomiseret til enten Viramune 400 mg depottabletter én gang dagligt (n = 295) eller fortsætte behandling med Viramune 200 mg tabletter to gange dagligt (n = 148). 
In study 1100.1526 (TRANxITION) patients on Viramune 200 mg immediate-release twice daily treatment for at least 18 weeks were randomised to either receive Viramune 400 mg prolonged-release once daily (n=295) or remain on their Viramune immediate-release treatment (n=148).
Ved dosering af Viramune i depotform sammen med et måltid med højt fedtindhold, var AUC0-24,ss og Cmin,ss for nevirapin henholdsvis ca. 94 % og 98 % af AUC0-24,ss og Cmin,ss, i forhold til patienter, der fik Viramune 200 mg tabletter. 
When Viramune prolonged-release was dosed with a high fat meal, the nevirapine AUC0-24,ss and Cmin,ss were approximately 94 % and 98 %, respectively, of the AUC0-24,ss and Cmin,ss measured when patients were dosed with Viramune immediate-release tablets.
Viramune tabletter indeholder lactose. 
Viramune tablets contain lactose (milk sugar).
Hvis en dosis ikke er blevet indtaget, og der er gået mere end 12 timer, skal patienten vente og tage den næste dosis som normalt. 
If a dose is missed and it is more than 12 hours later, the patient should only take the next dose at the usual time.
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE FLASKE ETIKET 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL
Hvis du oplever, at du bliver træt, skal du undgå at foretage dig ting, der kan være farlige, såsom bilkørsel eller brug af værktøj eller maskiner. 
If you experience fatigue you should avoid potentially hazardous tasks such as driving or using any tools or machines.
Hver depottablet indeholder 400 mg nevirapin. 
Each prolonged-release tablet contains 400 mg nevirapine.
I et enkeltdosisstudie (studie 1100.1485) undersøgtes nevirapins farmakokinetik hos 17 raske frivillige ved Viramune i depotform. 
The pharmacokinetics of nevirapine has been studied in a single dose study (study 1100.1485) of Viramune prolonged-release in 17 healthy volunteers.
VERxVE (studie 1100.1486) er et fase III-studie, hvor behandlingsnaive patienter fik Viramune 200 mg én gang dagligt i 14 dage og derefter blev randomiseret til at få enten Viramune 200 mg tabletter to gange dagligt eller Viramune 400 mg depottabletter én gang dagligt. 
VERxVE (study 1100.1486) is a phase 3 study in which treatment-naïve patients received Viramune 200 mg immediate-release once daily for 14 days and then were randomised to receive either Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily.
Den anbefalede dosis Viramune er én tablet 200 mg daglig i de første 14 dage (denne optrapningsperiode bør benyttes, idet den har vist sig at mindske hyppigheden af udslæt) efterfulgt af én tablet 200 mg 2 gange daglig i kombination med mindst to andre antiretrovirale lægemidler. 
The recommended dose of Viramune is one 200 mg tablet daily for the first 14 days (this lead-in period should be used because it has been found to lessen the frequency of rash), followed by one 200 mg tablet twice daily, in combination with at least two additional antiretroviral agents.
Den sædvanlige dosis er 1 tablet på 200 mg hver dag i de første 14 dage af behandlingen (optrapningsfase). 
The dose is one 200 mg tablet per day for the first 14 days of treatment (“lead-in” period).
Patienter, som afbryder behandling med nevirapin i mere end 7 dage, bør genstarte det anbefalede doseringsregimen med en 2 ugers optrapningsperiode med Viramune 200 mg. 
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing regimen using the two week lead-in period of Viramune immediate-release.